Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05615636 · ClinicalTrials.gov registry record · Phase 2

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

A Phase 2 study of Hodgkin Lymphoma and B-cell Lymphoma, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
36
Enrollment target
1
Study location

NCT05615636 is a Phase 2 study of Hodgkin Lymphoma and B-cell Lymphoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05615636, a Phase 2 study of Hodgkin Lymphoma and B-cell Lymphoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

Conditions Studied

Hodgkin Lymphoma B-cell Lymphoma Relapsed B-cell NHL

Interventions

  • DRUG Mosunetuzumab
  • DRUG Lenalidomide
  • DRUG Polatuzumab vedotin
  • DRUG Tafasitamab

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2023-04-28
Est. Completion 2027-08-19
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05615636

The ClinicalTrials.gov registry entry for NCT05615636 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (78% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Mosunetuzumab is the first listed.

NCT05615636 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05615636 about?

NCT05615636 is a clinical study titled "A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL". To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

What is the current status of trial NCT05615636?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2023-04-28. Estimated completion is 2027-08-19.

What conditions does trial NCT05615636 study?

This clinical trial studies the following conditions: Hodgkin Lymphoma, B-cell Lymphoma, Relapsed B-cell NHL.

What interventions are being tested in trial NCT05615636?

The interventions under investigation include: Mosunetuzumab (DRUG), Lenalidomide (DRUG), Polatuzumab vedotin (DRUG), Tafasitamab (DRUG).

Who is sponsoring clinical trial NCT05615636?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05615636 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hodgkin Lymphoma

All registered trials for this condition

B-cell Lymphoma

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.